<result><Target><Item><Target_ID> 2049</Target_ID>
<Target_Name>Extracellular domain of vascular endothelial growth factor receptor 3 (EC:2.7.10.1) (VEGFR-3)</Target_Name>
<Target_Type>Protein&gt;Receptor</Target_Type>
<Target_Sequence>P35917[25-770]</Target_Sequence>
<Synonyms>Alternative name(s) for VEGFR-3:
Fms-like tyrosine kinase 4
FLT-4
Tyrosine-protein kinase receptor FLT4</Synonyms>
<Target_Source>Mus musculus (Mouse):10090</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 2050</Target_ID>
<Target_Name>Polycrystalline SnO powder</Target_Name>
<Target_Type>Inorganic molecules or materials</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>None</Target_Source>
<Target_Structure></Target_Structure>
<Comments>Polycrystalline SnO powder (tin(II) oxide 99.9%; 100 Mesh Powder) was purchased from Alfa Aesar, Haverhill, MA, USA.</Comments>
</Item><Item><Target_ID> 2051</Target_ID>
<Target_Name>Olfactory bulk</Target_Name>
<Target_Type>Organ and tissue</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Mus musculus (Mouse):10090</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 2052</Target_ID>
<Target_Name>Hemisphere</Target_Name>
<Target_Type>Organ and tissue</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Mus musculus (Mouse):10090</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 2053</Target_ID>
<Target_Name>Cerebellum</Target_Name>
<Target_Type>Organ and tissue</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Mus musculus (Mouse):10090</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 2054</Target_ID>
<Target_Name>Brain</Target_Name>
<Target_Type>Organ and tissue</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Mus musculus (Mouse):10090</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 2055</Target_ID>
<Target_Name>Blood</Target_Name>
<Target_Type>Miscellaneous</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Rattus norvegicus (Rat):10116</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 2056</Target_ID>
<Target_Name>Chondroitin-4-sulfate, C4S</Target_Name>
<Target_Type>Organic molecules or materials</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>None</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 2057</Target_ID>
<Target_Name>Cysteine protease CP16160</Target_Name>
<Target_Type>Protein&gt;Enzyme</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Giardia assemblage A WB isolate</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 2058</Target_ID>
<Target_Name>Natalizumab</Target_Name>
<Target_Type>Protein&gt;Monoclonal antibody</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Mus musculus (Mouse):10090</Target_Source>
<Target_Structure></Target_Structure>
<Comments>Natalizumab (marketed as Tysabri) is the top selling biologic drug indicated for multiple sclerosis (MS) and has been used to treat 177,800 patients worldwide as of November 2017. Natalizumab is highly effective in treating MS patients; in the AFFIRM study, natalizumab was shown to reduce sustained physical disability by 42% relative to placebo. Natalizumab is a humanized recombinant IgG4 mAb that targets the α4 chain of α4β1 integrin (also known as very late activation antigen 4; VLA-4) and a4β7 integrin (LPAM-1). It is thought to function by blocking migration of immune cells across the blood-brain barrier into the central nervous system (CNS), thus suppressing inflammation in patients with relapsing-remitting multiple sclerosis.</Comments>
</Item><Item><Target_ID> 2059</Target_ID>
<Target_Name>Human bladder cancer cell line RT112</Target_Name>
<Target_Type>Cell</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments>The human bladder cancer cell line RT112 was obtained from the Cell Culture Center of the Institute of Basic Medical Science (Chinese Academy of Medical Sciences) in 2016.</Comments>
</Item><Item><Target_ID> 2060</Target_ID>
<Target_Name>Hepatitis A virus cellular receptor 1, HAVcr-1</Target_Name>
<Target_Type>Protein&gt;Receptor</Target_Type>
<Target_Sequence>Q96D42</Target_Sequence>
<Synonyms>Kidney injury molecule 1
KIM-1
T-cell immunoglobulin and mucin domain-containing protein 1
TIMD-1
T-cell immunoglobulin mucin receptor 1
TIM
TIM-1
T-cell membrane protein 1
CD_antigen: CD365</Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure>5DZO, 5F70</Target_Structure>
<Comments>Kidney injury molecule-1 (KIM-1), also known as hepatitis A virus cellular receptor-1 and T cell Ig mucin-1, is a transmembrane protein, which is not overexpressed in normal kidneys, but is significantly upregulated in damaged kidney tubular epithelial cells in toxic and ischemic acute kidney injury. KIM-1 is comprised of an extracellular segment containing a mucin domain and six cysteine Ig-like domains and a cytosolic segment containing a tyrosine kinase phosphorylation motif.</Comments>
</Item><Item><Target_ID> 2061</Target_ID>
<Target_Name>Glycoprotein 4, Protein GP4</Target_Name>
<Target_Type>Protein&gt;Others</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Porcine reproductive and respiratory syndrome virus (PRRSV)</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 2062</Target_ID>
<Target_Name>Human breast cancer cell line MCF7</Target_Name>
<Target_Type>Cell</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments>MCF7 (human breast cancer) cell line was obtained from Institute of Basic Medical Science, Chinese Academy of Medical Science (Beijing, China).</Comments>
</Item><Item><Target_ID> 2063</Target_ID>
<Target_Name>IgG from tegumentary leishmaniasis (TL) patients</Target_Name>
<Target_Type>Protein&gt;Polyclonal antibody</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments>The purification of IgG antibodies from sera of tegumentary leishmaniasis (TL) patients (n = 12) was performed.</Comments>
</Item><Item><Target_ID> 2064</Target_ID>
<Target_Name>Serum 13003 from patients sensitized to soy bean</Target_Name>
<Target_Type>Protein&gt;Polyclonal antibody</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 2067</Target_ID>
<Target_Name>Serum 13007 from patients sensitized to soy bean</Target_Name>
<Target_Type>Protein&gt;Polyclonal antibody</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 2068</Target_ID>
<Target_Name>Serum 13016 from patients sensitized to soy bean</Target_Name>
<Target_Type>Protein&gt;Polyclonal antibody</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 2069</Target_ID>
<Target_Name>Serum 14012 from patients sensitized to soy bean</Target_Name>
<Target_Type>Protein&gt;Polyclonal antibody</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 2070</Target_ID>
<Target_Name>Serum 13002 from patients sensitized to soy bean</Target_Name>
<Target_Type>Protein&gt;Polyclonal antibody</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 2071</Target_ID>
<Target_Name>Serum 13021 from patients sensitized to soy bean</Target_Name>
<Target_Type>Protein&gt;Polyclonal antibody</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 2072</Target_ID>
<Target_Name>Serum 13001 from patients sensitized to soy bean</Target_Name>
<Target_Type>Protein&gt;Polyclonal antibody</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 2073</Target_ID>
<Target_Name>IgE from patients with allergy to Scylla paramamosain AK</Target_Name>
<Target_Type>Protein&gt;Polyclonal antibody</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 2074</Target_ID>
<Target_Name>IgE from patients with allergy to Scylla paramamosain SCP</Target_Name>
<Target_Type>Protein&gt;Polyclonal antibody</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 2075</Target_ID>
<Target_Name>IgE from patients with allergy to Scylla paramamosain TIM</Target_Name>
<Target_Type>Protein&gt;Polyclonal antibody</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item></Target></result>